CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity
CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity
复制标题
DOI：
10.1002/ijc.22476
复制
发表时间：
2007-04-01
影响因子：
6.4
通讯作者：
Gu, Jianren
中科院分区：
文献类型：
--
作者：
Yin, Shengyong;Li, Jinjun;Gu, Jianren
最近越来越多的报道数据表明，只有一小部分癌细胞具有启动包括白血病和实体瘤在内的恶性肿瘤的能力，这是基于对这些细胞在原发癌中表现出明显的表面标记模式的研究。CD133是一种可能的造血和神经干细胞标记物，也被认为是脑和前列腺癌的致癌标记物。我们假设CD133是一个与肿瘤发生密切相关的标志物，因为有报道CD133在与肝癌发生密切相关的人胎肝和修复肝组织中表达。我们的研究结果表明，在人肝细胞癌细胞系和原发肝细胞癌组织中确实存在少量CD133阳性细胞。在SMMC-7721细胞系中，MACS分离的CD133(+)细胞与CD133(-)肝癌细胞相比，具有更高的致瘤性和克隆形成能力。CD133可能是肝细胞癌干细胞样细胞的标志之一的暗示有待进一步研究。(C)2007年Wiley-Liss，Inc.
Recently increasing reported data have suggested that only a small subset of cancer cells possess capability to initiate malignancies including leukemia and solid tumors, which was based on investigation in these cells displaying a distinct surface marker pattern within the primary cancers. CD133 is a putative hematopoietic and neuronal stem-cell marker, which was also considered as a tumorigenic marker in brain and prostate cancer. We hypothesized that CD133 was a marker closely correlated with tumorigenicity, since it was reported that CD133 expressed in human fetal liver and repairing liver tissues, which tightly associated with hepatocarcinogenesis. Our findings showed that a small population of CD133 positive cells indeed exists in human hepatocellular carcinoma (HCC) cell lines and primary HCC tissues. From SMMC-7721 cell line, CD133(+) cells isolated by MACS manifested high tumorigenecity and clonogenicity as compared with CD133(-) HCC cells. The implication that CD133 might be one of the markers for HCC cancer stem-like cells needed further investigation. (c) 2007 Wiley-Liss, Inc.